National Guideline Clearinghouse | Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion.
National Institute for Health and Care Excellence (NICE)
December 2, 2013
Guideline Title
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion.
Bibliographic Source(s)
| National Institute for Health and Care Excellence (NICE). Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. London (UK): National Institute for Health and Care Excellence (NICE); 2013 May. 62 p. (Technology appraisal guidance; no. 283). |
Guideline Status
This is the current release of the guideline.
No hay comentarios:
Publicar un comentario